Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK pays $50m upfront to tap Immatics’ cell therapy platform

It’s a similar approach to CAR-T therapy, but according to Immatics TCRs should have broader utility because they can be targeted at proteins inside cancer cells. ... Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’

Latest news

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    The US Food and Drug Administration has accepted an application for Bristol-Myers Squibb’s CAR-T therapy lisocabtagene maraleucel, kick-starting a priority review of the drug. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline

  • Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

    Thankfully for BMS, it wasn’t only Celgene’s drugs that caused the revenue surge. ... $94m. Meanwhile, Caforio is confident that Opdivo’s expected return to growth – plus a series of upcoming launches like multiple sclerosis drugluspatercept) in

  • EMA begins review of Kite’s CAR-T for mantle cell lymphoma EMA begins review of Kite’s CAR-T for mantle cell lymphoma

    If approved will become first CAR-T therapy for MCL. The European Medicines Agency (EMA) has begun its review of Gilead subsidiary Kite’s next-generation CAR-T therapy KTE-X19. . ... The first CAR-T therapy to be approved was Novartis’ Kymriah back

  • EU grants conditional approval to Roche's lymphoma drug Polivy EU grants conditional approval to Roche's lymphoma drug Polivy

    That lag, which will exist until off-the-shelf CAR-T therapies come to market, is one opportunity for Polivy. ... We estimated about 150 patients were treated with CAR-T in five months.

  • Newly-listed BioNTech buys Neon to boost cell therapy assets Newly-listed BioNTech buys Neon to boost cell therapy assets

    BioNTech said the deal would expand its CAR-T and T cell receptor (TCR) pipeline, allowing it to tap into Neon’s portfolio of cancer neoantigens – newly formed antigens that have ... executive. “I am particularly excited about the adoptive T cell

More from news
Approximately 46 fully matching, plus 148 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies.

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    We won’t compete directly with big vaccine companies, but may partner with them to support late phase product development and commercialisation. ... This is hard to know. The value of T cell approaches, especially CD8 T cells, has been shown by the

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics